Details

Autor(en) / Beteiligte

• Spaulding, Christian, MD, PhD
• Teiger, Emmanuel, MD, PhD
• Commeau, Philippe, MD
• Varenne, Olivier, MD, PhD
• Bramucci, Ezio, MD
• Slama, Michel, MD
• Beatt, Keavin, MD
• Tirouvanziam, Ashok, MD
• Polonski, Lech, MD
• Stella, Pieter R., MD, PhD
• Clugston, Richard, MD
• Fajadet, Jean, MD
• de Boisgelin, Xavier, MD
• Bode, Christophe, MD
• Carrié, Didier, MD
• Erglis, Andrejs, MD, PhD
• Merkely, Bela, MD
• Hosten, Stefan, PhD
• Cebrian, Ana, PhD
• Wang, Patrick, MD, MPH
• Stoll, Hans-Peter, MD
• Henry, Patrick, MD

Titel

Four-Year Follow-Up of TYPHOON (Trial to Assess the Use of the CYPHer Sirolimus-Eluting Coronary Stent in Acute Myocardial Infarction Treated With BallOON Angioplasty)

Ist Teil von

• JACC. Cardiovascular interventions, 2011, Vol.4 (1), p.14-23

Ort / Verlag

United States: Elsevier Inc

Erscheinungsjahr

2011

Quelle

Elsevier ScienceDirect Journals

Beschreibungen/Notizen

• Objectives The aim of this study was to assess the long-term safety and efficacy of the CYPHER (Cordis, Johnson and Johnson, Bridgewater, New Jersey) sirolimus-eluting coronary stent (SES) in percutaneous coronary intervention (PCI) for ST-segment elevation myocardial infarction (STEMI). Background Concern over the safety of drug-eluting stents implanted during PCI for STEMI remains, and long-term follow-up from randomized trials are necessary. TYPHOON (Trial to assess the use of the cYPHer sirolimus-eluting stent in acute myocardial infarction treated with ballOON angioplasty) randomized 712 patients with STEMI treated by primary PCI to receive either SES (n = 355) or bare-metal stents (BMS) (n = 357). The primary end point, target vessel failure at 1 year, was significantly lower in the SES group than in the BMS group (7.3% vs. 14.3%, p = 0.004) with no increase in adverse events. Methods A 4-year follow-up was performed. Complete data were available in 501 patients (70%), and the survival status is known in 580 patients (81%). Results Freedom from target lesion revascularization (TLR) at 4 years was significantly better in the SES group (92.4% vs. 85.1%; p = 0.002); there were no significant differences in freedom from cardiac death (97.6% and 95.9%; p = 0.37) or freedom from repeat myocardial infarction (94.8% and 95.6%; p = 0.85) between the SES and BMS groups. No difference in definite/probable stent thrombosis was noted at 4 years (SES: 4.4%, BMS: 4.8%, p = 0.83). In the 580 patients with known survival status at 4 years, the all-cause death rate was 5.8% in the SES and 7.0% in the BMS group (p = 0.61). Conclusions In the 70% of patients with complete follow-up at 4 years, SES demonstrated sustained efficacy to reduce TLR with no difference in death, repeat myocardial infarction or stent thrombosis. (The Study to Assess AMI Treated With Balloon Angioplasty [TYPHOON]; NCT00232830 )